Titomic Unveils Plan to Redomicile in US via Shareholder Scheme

Titomic’s US Redomiciliation Strategy

In a decisive step to cement its foothold in the United States defense sector, Titomic Limited (ASX:TTT) has entered a binding Scheme Implementation Deed to redomicile its corporate structure from Australia to the US. The plan involves transferring all existing Titomic shares to a newly formed Delaware corporation, Titomic, Inc., with shareholders receiving CHESS Depositary Interests (CDIs) representing their stakes in the US entity. This move preserves shareholders’ proportional economic interests while maintaining an ASX listing via CDIs, a structure familiar to Australian investors.

Why the US? Defense Access and Capital Markets

The board’s unanimous endorsement of the scheme underscores the strategic advantages of a US base. By redomiciling, Titomic aims to enhance participation in the expanding US defense industrial base, particularly engagements with Tier-1 prime contractors under the US Department of War. This is crucial given the regulatory landscape, including compliance with the International Traffic in Arms Regulations (ITAR), which governs sensitive defense technologies. The relocation is also designed to tap into the larger US market, aligning with the broader trend of sovereign manufacturing re-shoring, and to open doors to a wider investor pool previously constrained by geographic and regulatory barriers.

Access to lower-cost US debt and equity markets is another compelling factor, potentially accelerating growth. Furthermore, as a US corporation, Titomic positions itself favorably for future mergers, acquisitions, or even an initial public offering on a US exchange, a prospect the company explicitly flags as a longer-term objective. This strategic rationale builds on the company’s recent moves, including securing major defense contracts and certifications, as detailed in its prior US redomicile planning approval and aerospace and defense contracts announcements.

Mechanics of the Scheme and Shareholder Impact

The proposed scheme, subject to Federal Court of Australia approval, shareholder vote, and regulatory consents, will see each Titomic shareholder receive one Titomic, Inc. CDI for every 25 Titomic Limited shares held at the record date. The board and management team will remain unchanged post-transaction, providing continuity amid structural change. Option and performance rights holders will also maintain equivalent economic interests, contingent on executing binding amendments to their agreements.

For shareholders classified as ineligible foreign holders, a sale facility will be established whereby their CDIs will be sold on their behalf, with net proceeds distributed, a standard approach to navigating cross-border securities regulations. The company has engaged RSM Corporate Australia to provide an independent expert report on the scheme’s merits, expected to be included in the Scheme Booklet to be distributed in early July 2026.

Regulatory and Procedural Roadmap

The timeline anticipates key milestones including the first court hearing and Scheme Booklet dispatch in early July, a shareholder meeting in late July, and final court approval and scheme effectiveness by mid-August 2026. Titomic will then delist from the ASX, with trading in Titomic US HoldCo CDIs commencing on a deferred basis shortly after, transitioning to normal settlement cycles by late August. The company has retained Norton Rose Fulbright Australia and Fluet & Associates, PLLC as legal advisors, reflecting the cross-jurisdictional complexity of the transaction.

Board’s Stance and Shareholder Considerations

The board’s unanimous recommendation to vote in favor is conditioned on the independent expert concluding the scheme is in shareholders’ best interests and no superior proposal emerging. Directors have committed to vote their holdings in favor. The company cautions that the scheme is subject to multiple conditions precedent, including regulatory approvals and court orders, all of which carry inherent uncertainties. Investors should weigh the potential for enhanced US market access against the procedural risks and the impact of the sale facility on certain foreign holders.